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Abstract
Chromosomal translocations can lead to the formation of chimeric genes encoding fusion proteins such as PML/RARa,
PLZF/RARa, and AML-1/ETO, which are able to induce and maintain acute myeloid leukemia (AML). One key mechanism in
leukemogenesis is increased self renewal of leukemic stem cells via aberrant activation of the Wnt signaling pathway. Either
X-RAR, PML/RARa and PLZF/RARa or AML-1/ETO activate Wnt signaling by upregulating c-catenin and b-catenin. In a
prospective study, a lower risk of leukemia was observed with aspirin use, which is consistent with numerous studies
reporting an inverse association of aspirin with other cancers. Furthermore, a reduction in leukemia risk was associated with
use of non-steroidal anti-inflammatory drug (NSAID), where the effects on AML risk was FAB subtype-specific. To better
investigate whether NSAID treatment is effective, we used Sulindac Sulfide in X-RARa-positive progenitor cell models.
Sulindac Sulfide (SSi) is a derivative of Sulindac, a NSAID known to inactivate Wnt signaling. We found that SSi
downregulated both b-catenin and c-catenin in X-RARa-expressing cells and reversed the leukemic phenotype by reducing
stem cell capacity and increasing differentiation potential in X-RARa-positive HSCs. The data presented herein show that SSi
inhibits the leukemic cell growth as well as hematopoietic progenitors cells (HPCs) expressing PML/RARa, and it indicates
that Sulindac is a valid molecular therapeutic approach that should be further validated using in vivo leukemia models and
in clinical settings.
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Introduction
More than 60% of acute myeloid leukemia (AML) cases involve
specific chromosomal aberrations, mainly translocations. Ninety-
seven percent of acute promyelocytic leukemia (APL) patients
harbor the t(15;17) mutation, and less than 2% harbor the t(11;17)
mutation, which leads to the formation of chimeric genes that
encode the PML/RARa and PLZF/RARa (X-RARa) fusion
proteins. X-RARa induce and maintain the leukemic phenotype
by blocking terminal differentiation and increasing the self-renewal
potential of leukemic stem cells (LSCs) [1,2,3]. One of the key
mechanisms by which X-RARa increases LSC self-renewal is the
activation of the Wnt signaling pathway [2,4]. X-RARa activates
Wnt signaling by upregulating c-catenin and b-catenin at the
transcriptional level [4]. Activation of Wnt signaling augments self-
renewal of normal HSCs and LSCs [4,5,6].
Accumulation of b- and c-catenin and subsequent transcrip-
tional activation of T-cell-factor/lymphoid-enhancer-factor (TCF/
LEF) family members facilitates the development of leukemia.
Therefore, prevention of c-catenin accumulation is an attractive
target for chemotherapeutic-agents.
Activation of b-catenin plays a critical role in the development
of colorectal cancer and has been implicated in prostate and breast
cancer [7,8,9,10,11,12,13]. In the majority of these cases, aberrant
activation of Wnt signaling depends on mutations in the APC or b-
catenin genes that alter their interaction with axin and lead to
release of b-catenin from its cytoplasmic destruction complex. In
this complex, b-catenin is targeted for proteasomal degradation by
phosphorylation via GSK3b [14,15,16]. Unphosphorylated b-
catenin accumulates in the nucleus, where it associates with TCF/
LEF family members and various transcription co-factors
[17,18,19]. The resulting multi-protein complexes regulate
expression of genes that are important for proliferation, differen-
tiation, and apoptosis [13,20].
Non-steroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen, indomethacin, phenoprofen, and naproxen, inhibit
the activity of b-catenin-dependent reporter genes in malignant
cell lines and induce b-catenin degradation [21,22,23,24,25,26,27].
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22540Moreover, the colonic polyps of patients treated with NSAIDs show
reduced nuclear accumulation of b-catenin [21]. NSAIDs inhibit
both b-catenin activity and stability [23,24]. Nevertheless, the
molecular mechanism of NSAID-mediated inhibition of b-catenin
remains unclear.
Sulindac reduces the size and number of colorectal tumors in
patients suffering from familial adenomatous polyposis, a pre-
cancerous lesion that invariably develops into colon carcinoma if
left untreated [28]. Sulindac metalabolizes into Sulindac sulfon
(SSo) and Sulindac sulfide (SSi), both of which inhibit cell growth
by inducing apoptosis in colon cancer cells. SSo has a more
pronounced effect than SSi [29]. Notably, SSo exerts also a
chemo-preventive effect on the development of colon cancer [30].
SSi is a dual COX-1/-2 inhibitor, whereas SSo does not show any
inhibitory effect on COX enzymes. This result indicates that the
effects of Sulindac are independent of its ability to inhibit COX-1
and COX-2.
Here, we investigated the effects of Sulindac derivatives on the
X-RARa-induced leukemic phenotype to explore the potential of
NSAIDs as a novel therapeutic approach for acute leukemia.
Materials and Methods
Cell lines and chemicals
NB4 and KG-1 cell lines were obtained from the German
Resource Centre for Biological Material, Braunschweig, Germany
and maintained in RPMI 1640 with 10% fetal calf serum
(FCS)(Invitrogen, Karlsruhe, Germany). Additionally, the KG-1
cells were maintained in serum-free X-Vivo10 medium (Cambrex,
Verviers, Belgium). Phoenix and 293 cells were cultured in
DMEM with 10% FCS. SSi and SSo (Sigma, Steinheim,
Germany) were dissolved in DMSO at a concentration of
73.4 mM and 146.9 mM, respectively, for stock solutions, and
then appropriately diluted in the medium. Apoptosis was assessed
by 7-amino-actinomycin (7AAD; Sigma) staining.
Plasmids
The retroviral vectors PINCO-PML/RARa, PINCO-c-cate-
nin, and PINCO-PLZF/RARa were described previously[3].
PINCO-HA-b-catenin-S33A was created from pCMMBC-b-
catenin-S33A (kindly provided by A. Starzinski-Powitz, Frankfurt
University, Germany), using the Gateway system according to the
manufacturer’s instructions (Invitrogen). The TopFlash/FopFlash
system and the Renilla luciferase pRL-TK construct (Promega,
Mannheim, Germany) were described previously [31].
Transactivation assays
The 293 cells were co-transfected with pCDNA3, pC3-PML/
RARa, or pC2MMBC-b-catenin-S33A expression plasmids and
pRT-LK, pGL3-OT, or pGL3-OF (the pGL3-OT promoter
contains three TCF/LEF binding sites, whereas pGL3-OF
contains mutated, inactive binding sites and is a negative control)
using the calcium-phosphate method. Eight hours after transfec-
tion, each sample was subdivided and exposed either to 0.02%
DMSO or 100 mM SSi. After an additional 24 h, the luciferase
activity was determined using the ‘‘Dual-Luciferase Reporter
Assay’’ according to the manufacturer’s instructions (Promega). All
assays were normalized to co-transfected Renilla activity.
Western blotting
Western blotting was performed according to widely established
protocols. The antibodies used were the following: anti-RARa,
anti-c-catenin (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-b-catenin (Cell Signaling, Frankfurt, Germany), anti-active
b-catenin (Upstate, Charlottesville, VA, USA), anti-a-tubulin
(NeoMarkers, Freemont, CA, USA), and anti-b-actin (Abcam,
Cambridge, UK).
Real-time PCR-TaqMan (qRT-PCR)
Total RNA and first strand DNA were obtained according to
standard protocols. TaqMan-PCR was performed in triplicate
using the ABI PRISM 7700 (Applied Biosystems, Foster City, CA,
USA). The related ‘‘assays-on-demand’’ for LEF1, CyclinD1 and
Axin2 transcripts were used according to the manufacturer’s
instructions (Assay-IDs: LEF1 - Mm0550265_m1; CyclinD1 -
Mm0432359_m1; Axin2 - Mm00443610_m1)(Applied Biosys-
tems). CT values were exported into an OpenOfficeCalc work-
sheet for calculation of fold changes using the comparative CT
method. The target amount was normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Assay-ID: Mm99999915_g1)
using the 2
-DDCT method.
Isolation of Sca1
+/lin
2 HPCs
Sca1
+/lin
2 HSCs were isolated from 8 12-week-old C57BL/6N
female mice (Harlan, Borchen Germany). Bone marrow (BM) was
harvested from femurs and tibiae by flushing the bones. The cells
were ‘‘lineage depleted’’ using the ‘‘MACS Lineage Cell Depletion
Kit’’ (Myltenyi, Bergisch Gladbach, Germany). Sca1
+ cells were
then purified by immunomagnetic beads using the ‘‘EasySep
Mouse Sca1 Selection Cocktail’’ (StemCell Technologies) and pre-
stimulated for 2 days in medium containing mIL-3 (20 ng/mL),
mIL-6 (20 ng/mL), and mSCF (100 ng/mL)(Cell Concepts).
Retroviral transduction
Phoenix packaging cells were transfected with retroviral vectors
as described previously [3] 2 and 3 days post-transfection. Target
cells were plated onto retronectin-coated (Takara-Shuzo, Shiga,
Japan), non-tissue-culture 24-well plates and exposed to the
retroviral supernatant for 3 hours at 37uC in the presence of
4 mg/ml polybrene (Sigma). The infection efficiency was at least
70%, as assessed by detection of GFP-positive cells.
Replating efficiency, differentiation
At 5 days post-infection, Sca1
+/lin
2 cells were plated at 56103
cells/mL in methylcellulose containing mIL-3 (20 ng/mL), mIL-6
(20 ng/mL), and mSCF (100 ng/mL) (StemCell Technologies) in
the presence of either 0.02% DMSO or 100 mM SSi. The number
of colonies was determined 10 days after plating. The cells were
harvested by thorough washing, stained with specific antibodies for
the detection of differentiation, and plated at 56103 cells/plate in
methylcellulose to determine replating efficiency via serial
replating. Differentiation was assessed by expression of c-Kit,
Sca1, Gr-1, and Mac-1 (BD/Pharmingen).
Proliferation competition assay (PCA)
All animal studies were conducted in accordance with national
animal protection laws (Regierungspra ¨sidium Darmstadt - F 39/
06). Sca1
+/lin
2 cells isolated from C57BL/6N mice were
retrovirally transduced and cultivated in medium with 10%
FCS, mIL-6, mSCF, and mIL-3 for 7 days upon exposure to either
40 mM SSi or 0.02% DMSO. At days 2, 4, and 7 after
transduction, GFP expression was measured, and the GFP ratio
between SSi- and vehicle-treated cells was calculated.
Colony forming unit - spleen day 12 assay (CFU-S12)
In this study, 104 Sca1
+/lin
2 cells were retrovirally transduced,
cultivated and treated as described above. The cells were then
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sacrificed 12 days later. Spleens were harvested and fixed with
Tellysniczky’s fixative. Colonies were counted as described
previously [32].
Competitive repopulation assay (CRA)
CD45.1
+/Sca1
+/lin
2 cells that were retrovirally transduced,
cultivated, and treated as described above were injected into
lethally irradiated (11 Gy) CD45.2
+ female recipients with 56105
Figure 1. The effect of Sulindac derivatives on the expression of b-catenin and c-catenin in PML/RARa-positive leukemic cells.
Protein expression of active b-catenin, total b-catenin, c-catenin and PML/RARa was assessed by western blot analysis with the indicated antibodies.
(A) Patient-derived PML/RARa-positive NB4 cells treated with SSo (200 mM), SSi (200 mM) or 0.02% DMSO at 24 h and 48 h. (B) PML/RARa-expressing
KG-1 cells treated at the cell type-specific IC50 (100 mM - SSi, 360 mM - SSo and 0.02% DMSO) at 72 h. Control - empty-vector-transfected cells; a-a-
tubulin-loading control. (C–D) protein quantification of western blots presented in panel A and B, the bars represent the band intensity relative to the
intensity of the tubulin bands reveled with a S-800 Densitometer and the Quantity One software (Bio-Rad).
doi:10.1371/journal.pone.0022540.g001
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+ BM cells. The proportion of CD45.1
+ donor cell-derived
hematopoietic cells was determined using FACS of either BM or
spleen MNCs.
Statistical analysis
Statistical significance was determined by the unpaired
Student’s t-test and Log-rank (Mantel-Cox) test using the
GraphPad Prism software (GraphPad, San Diego, CA). A
p,0.05 value was considered significant.
Results
Sulindac derivatives downregulate b-catenin and
c-catenin, key mediators of Wnt signaling in
PML/RARa-positive leukemic cells
X-RARa-mediated leukemogenesis is related to Wnt signal-
ing activation by upregulation of b-catenin and c-catenin [3,4].
NSAIDs, such as Sulindac and its derivatives, are known to
inhibit Wnt signaling in colon carcinoma cells by inducing b-
catenin degradation [33]. Therefore, we wondered whether
pharmacologically active Sulindac derivatives could also inter-
fere with the leukemogenic potential of PML/RARa.W e
investigated the effects of Sulindac derivatives, Sulindac sulfon
(SSo) and Sulindac Sulfide (SSi), on the expression levels of b-
catenin and c-catenin in patient-derived NB4 cells using western
blot analysis. We found that SSo slightly reduced active b-
catenin after 24 h, but neither total b-catenin nor c-catenin.
Conversely, SSi downregulated expression of total b-catenin
and c-catenin as well as active b-catenin starting at 24 h. This
effect had the largest magnitude at 48 h. SSi (but not SSo) was
also able to downregulate the expression of PML/RARa at 48 h
(Figure 1A). Notably, SSo seemed to stabilize PML/RARa at
48 h.
To investigate whether the effects of the Sulindac derivatives
were either 1) genetically determined by the presence of t(15;17)
and thus mediated by PML/RARa, 2) a feature of promyelocytes,
or 3) a general effect of transformed cells, we studied their effects
on expression of b-catenin and c-catenin in KG-1 cells stably
transfected with PML/RARa compared with mock transfected
KG-1 control cells. We exposed KG-1 cells to 360 mM SSo and
100 mM SSi (the specific IC50s for apoptosis induction, data not
shown). In Figure 1B, we show that SSo and SSi downregulated
active b-catenin as well as total b-catenin and c-catenin in both
control cells and PML/RARa-positive KG-1 cells.
In summary, these data show that SSi targets b-catenin and c-
catenin more efficiently than SSo, an effect apparently not
mediated by PML/RARa.
Effects of SSi (but not SSo) on APL cells occur at clinically
relevant dosages
The maximum plasma concentrations after either SSo or SSi
oral administration to patients were 100 mM and 50–100 mM,
respectively [21,34,35]. To examine clinical doses of SSo and SSi,
we compared the capacity of these compounds to induce apoptosis
in NB4 cells at concentrations between 0 and 150 mM. As shown
in Figure 2, SSi induced physiologically relevant rates of apoptosis
within clinically achievable concentrations, between 75 and
100 mM, whereas 100 mM SSo induced only very limited
apoptosis. Based on these data, all subsequent studies were
performed using SSi.
SSi interferes with the aberrant replating efficiency of
X-RARa-expressing HSCs and that induced by active
b-catenin and c-catenin
Activated Wnt signaling is considered to be primarily
responsible for the aberrant biology of X-RARa-expressing HSCs.
Therefore, we studied the effects of SSi on the replating efficiency
of X-RARa-positive Sca1
+/lin
2 HPCs (Figure 3A). Here, we
report that SSi reduced not only the CFU number, but also the
number of serial replating rounds possible with cells expressing X-
Figure 2. Induction of apoptosis in patient-derived NB4 cells by Sulindac derivatives. Rate of apoptosis in patient-derived PML/RARa-
positive NB4 cells was assessed by 7AAD staining upon exposure to clinically achievable concentrations (50–150 mM) of SSi and SSo. Apoptosis was
measured after 72 h. Data are expressed as the mean of three independent experiments with standard deviation (SD). Statistical analysis was
performed using Student’s t-test (* - p,0.05; ** - p,0.01).
doi:10.1371/journal.pone.0022540.g002
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control cells. Withdrawal of SSi did not recover the replating
potency of HPCs expressing X-RARa, thus indicating that the
effect of SSi is irreversible (Figure 3B). The morphology of the
colonies was classified as type A, B, or C, according to Lavau and
co-workers [36]. In the first two rounds of plating, X-RARa-
positive cells displayed mainly type B colonies, with a dense
center surrounded by a halo of migrating cells (Figure 3C). Upon
further serial replatings, small, compact, typical types A colonies,
known to represent immature cells, were dominant [3]. Upon
treatment with SSi, the X-RARa-positive colonies exhibited a
clear type C morphology of diffuse colonies with mobile
differentiating cells, revealing a differentiation-inducing effect of
SSi (Figure 3C).
Expression of c-catenin increases the serial replating potential of
murine HSCs [3], and activation of b-catenin by Wnt ligands
induces increased self-renewal [5,37]. To determine whether SSi
inhibits these effects, we exposed Sca1
+/lin
2 HPCs, transduced
with either constitutively active b-catenin (S33A) or c-catenin, to
SSi. The S33A mutant harbors four mutated phosphorylation sites
(S33, S37, S41, S45), preventing its proteasomal degradation and
leading to constitutively active b-catenin. SSi decreased the
number of CFUs in single plating rounds and the overall replating
efficiency for HPCs expressing either active b-catenin or c-catenin
(Figure 3D).
In summary, these data provide evidence that SSi abrogates the
leukemogenic potential of X-RARa. Furthermore, SSi reversed
the effects of both b-catenin and c-catenin on HPCs.
Figure 3. Effect of SSi on the biology of X-RARa-, c-catenin- and constitutively active b-catenin-expressing murine HSCs. (A)
Experimental strategy. Sca1
+/lin
- BM cells were infected with the indicated retroviruses and plated in semi-solid medium with the indicated growth
factors to determine the serial plating potential in the presence of either 100 mM SSi or 0.02% DMSO. (B) Long-term serial replating (I–VII) of HSC and
X-RARa-positive HSC. SSi withdrawal after plating round V for PML/RARa-positive colonies and after plating round VI for PLZF/RARa-positive colonies.
(C) Colony morphology of plating rounds I, III, VI, and VII as well as SSi withdrawal. (D) Long-term serial replating (I–V) of c-catenin- and b-catenin-
S33A-positive HSC. Data are expressed as the mean of three independent experiments with SD. Control - empty vector; Q-SSi withdrawal; I–VII: serial
plating rounds.
doi:10.1371/journal.pone.0022540.g003
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That PML/RARa induces activation of Wnt signaling similar
to Wnt ligands and increases HSC self-renewal prompted us to ask
whether SSi interferes with Wnt signaling activation by PML/
RARa, assessed by TCF/LEF-dependent transactivation. There-
fore, we transduced 293 cells with PML/RARa and S33A as a
positive control (Figure 4A and 4B) and assessed Wnt signaling
activation by luciferase activity using the Topflash/Fopflash
system. PML/RARa and S33A induced promoter activation,
which decreased upon treatment with SSi (Figure 4A). Further-
more, we used qRT-PCR to investigate the effect of SSi on Wnt
signaling in X-RARa-positive Sca1
+/lin
2 HPCs via expression of
the Wnt target genes, LEF1, CyclinD1 and Axin2, in the
presence/absence of 40 mM SSi. As shown in Figure 4C,
expression of LEF1, cyclin D1 and Axin2 was inhibited by SSi
treatment in X-RARa-expressing Sca1
+/lin
2 HPCs. Taken
together, these data show that SSi reduce PML/RARa-mediated
aberrant activation of Wnt-signaling and downregulate Wnt-
specific target genes.
SSi reverses the X-RARa-induced differentiation block in
murine HSCs
One feature of the leukemic phenotype is inhibited differenti-
ation of early hematopoietic precursors. X-RARa inhibits terminal
differentiation in murine HSCs [3]. To study whether the effects of
SSi on replating efficiency leukemic HPCs were caused by reversal
of the differentiation block, we investigated the effects of clinical
doses of SSi on differentiation of X-RARa-expressing Sca1
+/lin
2
HPCs (Figure 5A). Differentiation was assessed by expression of
specific surface markers such as Gr-1, Mac-1, Sca1, and c-Kit. We
performed these experiments in liquid culture to demonstrate the
effects of SSi on mock-transduced control HPCs, which should
fully differentiate spontaneously in semi-solid medium. We found
that SSi induced differentiation despite the presence of X-RARa,
as demonstrated by an increase in Gr-1
+ and Mac-1
+ and decrease
in Sca1
+ and c-Kit
+ cells (Figure 5B). To assess whether SSi-
induced differentiation interfered with HSC proliferation, we
performed PCA experiments that compared X-RARa-expressing
HPCs to an empty vector control. The principle of the assay is
depicted in Figure 5C; HPCs were transduced with the PINCO
constructs, in which the LTR drives transgene expression. GFP
expression is driven by a CMV promoter. The effect of SSi was
demonstrated by detecting GFP-positive cells using FACS at 1
week. We found that SSi exposure led to reduced proliferation of
X-RARa-positive HPCs, with no such effect on control cells
(Figure 5D).
In summary, we provide evidence that SSi reverses the leukemic
differentiation block and decreases X-RARa-dependent prolifer-
ation.
SSi inhibits the short-term stem cell capacity of PML/
RARa- and PLZF/RARa-positive HPCs
Our data suggest that SSi interferes with the stem cell
maintenance capacity of X-RARa-positive HPCs. To confirm
this mechanism, we performed a CFU-S12 assay on X-RARa-
positive Sca1
+/lin
2 HPCs cultured for seven days in the presence/
absence of 40 mM SSi, to detect ‘‘short-term repopulating stem
cells’’ (ST-HSC) (Figure 6A) [38]. We found that the CFU-S12
number for X-RARa-positive HPCs was reduced upon exposure
to SSi (Figure 6B-C). The arrows indicate an example of a CFU in
the fixed spleens (Figure 6B), the number of CFUs is represented
in a bar graph (Figure 6C). The trend was not statistically
significant in PLZF/RARa-transduced cells, in contrast with
PML/RARa-positive HPCs; however, a trend toward a reduced
number of CFU-S12 was identified. Of note, we also observed a
‘‘paradoxical’’ effect of SSi on empty vector controls, as
demonstrated by an increased number of CFU-S12s compared
with vehicle-treated cells (Figure 6B–C).
Taken together, these data show that SSi reduces the ST-HSC
capacity of X-RARa-positive HPCs.
SSi inhibits the long-term stem cell capacity of PML/
RARa-positive HPCs
To determine whether SSi interferes with the capacity of X-
RARa to maintain long-term stem cell (LT-HSC) capacity, we
performed a CRA assay [38] on PML/RARa-positive Sca1
+/lin
2
HPCs cultured for seven days in the presence/absence of 40 mM
SSi (Figure 7A). The population density of LT-HSC was assessed
via CD45.1/CD45.2 chimerism, which demonstrates the capacity
of the PML/RARa-positive CD45.1
+ donor cells to compete the
Figure 4. Effect of SSi on PML/RARa-mediated Wnt signaling pathway activation. (A) Transactivation assay for Wnt-signaling-related TCF/
LEF-dependent transcription. Indicated expression vectors were co-transfected with either Topflash (OT) or Fopflash (OF) (the pGL3-OT promoter
contains three TCF/LEF binding sites, whereas pGL3-OF contains mutated inactive binding sites and is a negative control) reporter constructs into 293
cells and exposed them to either 100 mM SSi or 0.02% DMSO. After 48 h, luciferase activity was measured and normalized to co-transfected Renilla
activity. (B) Western blots for the expression of PML/RARa and S33A using the indicated antibodies, a-b-actin-loading control. (C) Effects of SSi on Wnt
target genes in X-RARa-positive Sca1
+/lin
- HPCs. Results are represented as 2
-DDCT values. Each experiment was performed three times in triplicate,
with similar results obtained each time. One representative experiment with SD is shown.
doi:10.1371/journal.pone.0022540.g004
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+ BM cells in lethally
irradiated CD45.2
+ recipients (Figure 7A). Upon exposure to
SSi, we found that after 8 months, the proportion of PML/
RARa-positive HPCs was significantly reduced in the BM and
spleens of recipient mice compared with untreated controls
(Figure 7B).
Taken together, these data show that SSi reduces the LT-HSC
capacity of PML/RARa-positive HPCs via inhibition of Wnt
signaling.
Discussion
The aim of this study was to explore the possibility of treating
leukemia cells with NSAIDs, which are known to inhibit Wnt
signaling in several solid tumor models [21,23,24,39]. Aberrant
Wnt signaling is a key event during pathogenesis of APL and other
leukemia [4,6,40,41].
Herein, we show for the first time that the NSAID, Sulindac,
interferes with the X-RARa-induced leukemic phenotype. These
effects include degradation of the key Wnt signaling mediators b-
and c-catenin and overcoming the inhibition of differentiation and
aberrant stem cell capacity.
In a prospective study, a lower risk of leukemia was associated
with the use of aspirin [42] consistent with numerous studies
reporting an inverse association of aspirin with other cancers.
Furthermore, the use of other NSAIDs demonstrated a reduction
in AML incidence, depending on the FAB classification [43]. Cell
lines such as KG1 (a cell line derived from an AML patient FAB
M2) show a sensitivity to Sulindac, independent of PML/RARa.
These data are consistent with the data showing that the use of
NSAIDs prevents this type of AML [43].
Furthermore, we show in our in vivo experiments that SSi
dramatically reduces the short- and long-term repopulating
efficiency of PML/RARa expressing HPCs, accompanied by
Figure 5. Effect of SSi on the X-RARa-induced phenotype in murine HSCs. (A) Experimental strategy. Sca1+/lin
- BM cells were infected with
the indicated retroviruses and maintained for one week in liquid culture with the indicated growth factors in the presence/absence of 40 mM SSi. (B)
Differentiation was assessed by the expression of Gr-1, Mac-1, c-Kit and Sca1. (C) Schematic representation of the proliferation competition assay
(PCA). (D) GFP expression in X-RARa-positive HPCs assessed by FACS analysis in the presence/absence of SSi at day 2, 4, and 7. One representative
result from three independent experiments is shown.
doi:10.1371/journal.pone.0022540.g005
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and Axin2. The data herein strongly suggest a novel mechanism
for Sulindac in leukemia compared with its mechanism in either
colon carcinoma or other solid tumors. We found that SSi had a
more pronounced effect than SSo, in contrast to the more
pronounced effect of SSo observed in colon carcinoma [29]. All
the effects of SSi on either differentiation or stem cell capacity
were demonstrated using clinical doses. Furthermore, we found
that SSi had a stronger effect on the expression of b- and c-catenin
compared with SSo, which also differs from observations in colon
carcinoma cells. Although both compounds diminished b- and c-
catenin expression, it is possible that the differences between SSi
and SSo were due to different efficiencies in downregulating b-
and c-catenin that were not detectable in our models. In colon
carcinoma cells, SSo is a known specific inhibitor of c-GMP
phosphodiesterase, which leads to increased c-GMP levels,
followed by activation of c-GMP-dependent kinases [44]. One
consequence of this could be alternative phosphorylation of b-
and/or c-catenin, directing these proteins to proteasomal
degradation [29,33]. Conversely, SSi-induced degradation of b-
and c-catenin has been described as independent of its COX-1/-2
inhibitory activity. The prominent COX-independent activities
associated with SSi are Raf inhibition and caspase activation
[45,46]. Raf inhibition can be excluded as the mechanism for
inhibition of the leukemic phenotype because Ras signaling is
apparently not involved in X-RARa-related leukemogenesis.
Notably, b-catenin is known to stabilize COX-2 mRNA [47].
Thus, the downregulation of b-catenin accompanied by parallel
inhibition of COX-2 might explain the stronger activity of SSi
compared with SSo in our models. Hence, our data indirectly
demonstrate that the effects of Sulindac derivatives on leukemic
cells via COX inhibitory activity cannot be completely excluded,
as SSo (not SSi) does not inhibit COX enzymes. Furthermore, SSi
showed an effect at a concentration in which it inhibits not only
COX but also the 5 lipoxygenase (5-LO), another key enzyme in
the arachidonic acid cascade [48].
SSi might exhibit a stronger effect on APL cells due to the
degradation of PML/RARa as well as b- and c-catenin in NB4
cells. Notably, SSi was also able to decrease the biological activity
of mutant b-catenin in murine HSCs, as evidenced by decreased
TCF/LEF-dependent transcription. This common effect can be
explained, by the downregulation of b-catenin by SSi via
phosphorylation-independent mechanisms [49]. These effects
may be mediated by SIAH upregulation, which is known to be
Figure 6. Effect of SSi on X-RARa-mediated aberrant stem cell capacity in murine HSC. (A) Experimental strategy for studying the ST-HSC
capacity of X-RARa-expressing HSCs (CFU-S12). Sca1
+/lin
- BM cells were infected with the indicated retroviruses and maintained for one week in liquid
culture with the indicated growth factors in the presence/absence of 40 mM SSi. Cells were inoculated into lethally irradiated (11Gy) recipients that
were then sacrificed at day 12 after transplantation. (B) Photographs of all the fixed spleen are shown, the arrows indicate an example of a CFU in the
fixed spleens. (C) Bulks represent the number of CFU-S12 expressed as the mean from three spleens with SD. Statistical analysis was performed using
Student’s t-test (* - p,0.05; ** - p,0.01).
doi:10.1371/journal.pone.0022540.g006
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the oncogenic agent responsible for initiation and maintenance of
the leukemic phenotype. Herein, we show that the combination of
PML/RARa and SSI activates the SIAH promoter (Figure S1 and
Data S1).
Recent data demonstrate that PML/RARa-induced self-
renewal of HSCs is mediated by the induction of p21
cip1/waf1,
and the synergism of both is essential for the maintenance of
leukemic stem cells [2].
The combined effects of SSi on Wnt signaling and PML/
RARa suggest a great potential for SSi as a novel therapeutic
approach in leukemic stem cell therapy. Supporting its thera-
peutic use, clinical concentrations of SSi reversed the X-RARa-
related differentiation block and aberrant stem cell capacity.
Notably, exposure to SSi led to an increase in stem cell capacity
for normal HSCs. This effect in normal cells might be due to SSi-
induced ERK1/2 activation, which has been shown to overcome
SSi-related cytotoxicity [51].
That SSi does not inhibit Wnt signaling selectively in X-RARa-
positive cells is not of high clinical importance because the
activation of Wnt signaling is only indispensable for LSCs, not for
normal HSCs [3,52,53] (Wang et al. 2010).
The clinical significance of our findings establishes that Sulindac
derivatives are not only chemo-preventatives in colon carcinoma
but also potentially novel compounds for use in maintenance
therapy to control residual disease. This finding is consistent with
recent data on the effects of NSAIDs in a MLL/AF9-induced
leukemia model [41]. In fact, the principal aim of maintenance
therapy is to control leukemic stem cells with compounds that have
few undesired side effects. Sulindac derivatives have long half-lives,
and renal and gastric toxicity can be easily controlled.
In summary, we provide a proof of principle that NSAIDs can
be used for ‘‘stem cell therapy’’ approaches in leukemia and
function by targeting Wnt signaling, which should be further
validated in in vivo leukemia models and clinical settings.
Supporting Information
Figure S1 Transactivation of the SIAH1 promoter. The
indicated transgenes were co-transfected with the SIAH1 promot-
er fragment -297-0 into 293 cells and exposed to either 100 mM
SSi or 0.02% DMSO. The data are the mean from two triplicate
experiments with SD (Data S1).
(TIF)
Data S1 Supporting information
(DOC)
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Figure 7. Effect of SSi on PML/RARa-mediated aberrant long-term stem cell capacity in murine HSC. (A) Experimental strategy for
studying the LT-HSC capacity of PML/RARa-expressing HSCs. Sca1
+/lin
- BM cells from CD45.1
+ mice were infected with the indicated retroviruses and
maintained for one week in liquid culture with the indicated growth factors in the presence/absence of 40 mM SSi. The cells were co-transplanted
with CD45.2
+ BM cells into lethally (11 Gy) irradiated CD45.2
+ recipient mice. (B) Donor chimerism 8 months after transplantation was used to
determine LT-HSC capacity in the BM and spleen. Statistical significance was determined using the Log-rank (Mantel-Cox) test (* ,0.05; ** ,0.01).
doi:10.1371/journal.pone.0022540.g007
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